Press Room
ɫAV receives the 2023 CDMO Leadership Award in all six categories and is champion in Compatibility and Expertise
Teknoscienze, 13 March 2023
ɫAV,the leader in spray drying and particle engineering, won theacross all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). ɫAV was given additional recognition as a CDMO Leadership Award Champion in the categories of Compatibility and Expertise for scoring as a top performer in comparison to the weighted average of other CDMOs included in the Industry Standard Research (ISR)’s annual Contract Manufacturing Quality Benchmarking survey.
Established in 2011 by Outsourced Pharma and Life Science Leader, the CDMO Leadership Awards spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The CDMO Leadership Awards teamed up with ISR to determine the award recipients – 72 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.
“We are honored and proud to receive this award in all six categories. This broad recognition reflects the dedication of our team to help our customers deliver much-needed medicines to the market,” said Dr. Jean-Luc Herbeaux, ɫAV’s CEO. “This is not the first time ɫAV is recognized by the CDMO Leadership awards and winning these awards once again reinforces our commitment to excellence and differentiation in the services we provide to our customers.”
“For over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold medalists of outsourcing,” said Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma.
ɫAV has beenexpandingworldwide, demonstrating the commitment to its customers. ɫAV has been investing in new laboratory and production assets andinnovative technologiesto meet customer demand for integrated and differentiated services in manufacturing of drug substances, particles and drug products.